[{"orgOrder":0,"company":"Elevar Therapeutics","sponsor":"Zukunftsfonds Heilbronn","pharmaFlowCategory":"D","amount":"$72.2 million","upfrontCash":"Undisclosed","newsHeadline":"Eleva Secures up to EUR 60 million to Advance a Drug Candidate, Appoints New Board Member","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Elevar Therapeutics"},{"orgOrder":0,"company":"Creative Medical Technology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Creative Medical Technology Holdings Files Patent based on Positive Data on Renal Failure using ImmCelz\u00ae Regenerative Immunotherapy","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Creative Medical Technology"},{"orgOrder":0,"company":"twoXAR Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"TwoXAR Pharmaceuticals Presents Preclinical Data Showing Significant Efficacy and Safety of Two Novel CKD Treatment Candidates","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"twoXAR Pharmaceutical"},{"orgOrder":0,"company":"Telara Pharma","sponsor":"Arch Biopartners","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Arch Biopartners Enters into Worldwide License Agreement with Telara Pharma to Re-Purpose Cilastatin for the Treatment and Prevention of Acute Kidney Injury","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"Approved","date":"April 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Telara Pharma"},{"orgOrder":0,"company":"Nephraegis Therapeutics","sponsor":"Xontogeny, LLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Nephraegis Therapeutics Launches with Seed Financing to Develop Small Molecules to Prevent and Treat Acute Kidney Injury (AKI)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Nephraegis Therapeutics"},{"orgOrder":0,"company":"Tribune Therapeutics","sponsor":"Healthcaps India","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Tribune Therapeutics Launches to Develop Novel Medicines Targeting a Wide Range of Fibrotic Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"SWEDEN","productType":"Undisclosed","productStatus":"Undisclosed","date":"June 2021","url1":"","url2":"","graph1":"Undisclosed","graph2":"Tribune Therapeutics"},{"orgOrder":0,"company":"Sinovent","sponsor":"Everest Medicines","pharmaFlowCategory":"D","amount":"$561.0 million","upfrontCash":"$12.0 million","newsHeadline":"Everest Medicines, Sinovent and SinoMab Announce Licensing Agreement for Global Development, Manufacturing and Commercialization of Novel BTK Inhibitor in Renal Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Sinovent"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q32 Bio to Present Preclinical Data on Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Q32 Bio"},{"orgOrder":0,"company":"Arrowhead Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Arrowhead Files for Regulatory Clearance to Begin Phase 1\/2a Study of ARO-C3 for Treatment of Complement Mediated Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Arrowhead Pharmaceuticals"},{"orgOrder":0,"company":"Q32 Bio","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Q32 Bio Presents Preclinical Data Supporting Next Generation Complement Inhibitor, ADX-097, at the American Society of Nephrology Kidney Week 2021","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Large molecule","graph2":"Q32 Bio"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Zhejiang Ausun Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Algernon Pharmaceuticals Begins Manufacturing of Repirinast and Launches New Chronic Kidney Disease Research Program","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Saniona","sponsor":"University of Arhus","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Saniona\u2019s Preclinical Candidate SAN903 Shows Robust Dampening of Fibrosis in Chronic Kidney Disease Model","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"DENMARK","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Saniona"},{"orgOrder":0,"company":"Transcenta Holding","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Transcenta was Selected to Present the Preclinical Data of TST004 at the 2022 ISN Frontiers Meetings of Complement Related Kidney Diseases","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"CHINA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"June 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Transcenta Holding"},{"orgOrder":0,"company":"Algernon Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Algernon Pharmaceuticals Provides Update on its Planned Phase 1 Repirinast Chronic Kidney Disease Study","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Algernon Pharmaceuticals"},{"orgOrder":0,"company":"Eligo Bioscience","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eligo Bioscience Receives FDA Orphan Drug Designation (ODD) and Rare Pediatric Disease (RPD) Designation for EB003 for the Prevention of Hemolytic Uremic Syndrome with First-in-class CRISPR-based medicine","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Eligo Bioscience"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Positive Results in Preclinical Model of Acute and Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"October 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Revelation Biosciences"},{"orgOrder":0,"company":"Maze Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Maze Therapeutics Presents Preclinical Data Highlighting Potential of APOL1 Inhibitor Program as a Treatment for Chronic Kidney Disease","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Maze Therapeutics"},{"orgOrder":0,"company":"Revelation Biosciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Revelation Biosciences"},{"orgOrder":0,"company":"IGAN Biosciences","sponsor":"Selecta Biosciences","pharmaFlowCategory":"D","amount":"$1.6 million","upfrontCash":"Undisclosed","newsHeadline":"Selecta Biosciences Announces Next Generation IgA Protease Clinical Candidate Selection for IgA Nephropathy Program","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"IGAN Biosciences"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
The selection of a next generation Immunoglobulin A (IgA) protease from IGAN Biosciences for its IgA nephropathy (IgAN) program, will lead Selecta Biosciences to pay IGAN Biosciences.
REVTx-300 is our proprietary formulation for systemic administration of PHAD and is being developed as a potential therapy for the treatment of acute and chronic organ disease including CKD, acute kidney injury (AKI), myocarditis, and NASH.
MZ-301 Is a Small Molecule Inhibitor of APOL1 Pore Function That Attenuates Albuminuria in a Mouse Model of APOL1-Mediated Kidney Disease,Potently blocked APOL1 and prevented APOL1-mediated killing of trypanosomes in a parasite viability assay.
REVTx-300 is proprietary formulation for systemic administration of PHAD and is being developed as a potential therapy for treatment of acute and chronic organ disease including chronic kidney disease, acute kidney injury (AKI), myocarditis, and nonalcoholic steatohepatitis.
EB003 is a first-in-class microbiome gene therapy designed, built, and optimized to target STEC bacteria in the gut of infected patients, leveraging Eligo’s unique expertise in synthetic biology, phage biology, genetic engineering, and bioinformatics.
In pre-clinical model of kidney fibrosis, NP-251 (repirinast) reduced fibrosis by 50% with statistical significance, showed improvement when given in combination with Telmisartan, which is BP lowering medication and is considered, standard of care treatment for CKD.
SAN903 was administrated daily during unilateral urinary obstruction the total fibrotic area was reduced by up to 43% (p>0.0001). SAN903 was well tolerated at all doses.
TST004 is a humanized mAb targeting mannose-binding protein-associated serine protease 2 (MASP2) and designed to prevent the inflammation and tissue damage mediated by lectin pathway complement activation.
Repirinast was originally developed by Mitsubishi Tanabe Pharma (“Mitsubishi”) and was sold and marketed in Japan under the brand name Romet™ for the treatment of asthma. Romet™ was marketed for over 25 years in Japan.
Arrowhead will proceed with AROC3-1001, a Phase 1/2a dose-escalating study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARO-C3 in up to 24 adult healthy volunteers and in up to 24 adult patients with paroxysmal nocturnal hemoglobinuria.